Effect of empagliflozin on ventricular arrhythmias in patients with type 2 diabetes treated with an implantable cardioverter-defibrillator: the EMPA-ICD trial.
Fujiki S, Iijima K, Nakagawa Y, Takahashi K, Okabe M, Kusano K, Owada S, Kondo Y, Tsujita K, Shimizu W, Tomita H, Watanabe M, Shoda M, Watanabe M, Tokano T, Murohara T, Kaneshiro T, Kato T, Hayashi H, Maemura K, Niwano S, Umemoto T, Yoshida H, Ota K, Tanaka T, Kitamura N, Node K, Minamino T; EMPA ICD investigators.
Fujiki S, et al.
Cardiovasc Diabetol. 2024 Jun 28;23(1):224. doi: 10.1186/s12933-024-02309-9.
Cardiovasc Diabetol. 2024.
PMID: 38943159
Free PMC article.
Clinical Trial.